PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

Preclinical data suggest that PIK3CA mutations predict response to PI3K/AKT/mTOR inhibitors. Concomitant KRAS or BRAF mutations may mediate resistance. Therefore tumors from patients referred to the Phase I Program for targeted therapy starting in October 2008 were analyzed for PIK3CA mutations usin...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Janku, Filip, Tsimberidou, Apostolia M., Garrido-Laguna, Ignacio, Wang, Xuemei, Luthra, Rajyalakshmi, Hong, David S., Naing, Aung, Falchook, Gerald S., Moroney, John W., Piha-Paul, Sarina A., Wheler, Jennifer J., Moulder, Stacy L., Fu, Siqing, Kurzrock, Razelle
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3072168/
https://ncbi.nlm.nih.gov/pubmed/21216929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0994
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires